Learning Objectives

Upon completion of the activity, participants should be able to:

• Discuss the presentation, diagnosis, and spectrum of CSCC
• Recognize patients at increased risk for locally advanced/metastatic CSCC
• Identify patients with CSCC who are likely to benefit from referral to/consultation with providers or a multidisciplinary team with expertise in advanced skin cancer
• Describe emerging treatments for more advanced cases that may require a systemic approach

Description:
In this activity, listen to CSCC expert Dr. Michael Wong discuss how to recognize risk for CSCC in your patients, as well as the emerging treatment options that are changing the way patients with CSCC are treated. Later, he is joined by Dr. Chrysalyne Schmults to review a patient case and discuss the optimal approach to multidisciplinary care for the patient.

Statement of Need:
Cutaneous squamous cell carcinoma (CSCC) is the second most common form of human cancer, and its incidence is on the rise. While most CSCC can be cured with office-based therapy, locally advanced/metastatic cases pose a significant risk for morbidity, impact on quality of life, and death. Treatment options have expanded to include newer immunotherapies, which hold new promise for patients with advanced disease. Both dermatologists and oncologists are involved in the management of locally advanced/metastatic CSCC, and both specialties face several challenges in optimizing care. In this education, learners will hear both perspectives on managing and treating CSCC.

Faculty

Chrysalyne D. Schmults, MD
Vice Chair, Surgical Oncology, Department of Dermatology, Brigham and Women’s Hospital
Director, Mohs and Dermatologic Surgery Center
Program Director, Micrographic Surgery and Dermatologic Oncology Fellowship Program
Associate Professor, Dermatology, Harvard Medical School

Michael K. Wong, MD, PhD, FRCPC
Professor, Cutaneous Cancers, Medical Oncology
Executive Director, Integration and Program Development, Cancer Network
MD Anderson Cancer Center

METHOD OF PARTICIPATION/HOW TO RECEIVE CREDIT
Technical Requirements: https://www.francefoundation.com/general-requirements.html

• There are no fees for participating in and receiving credit for this activity.
• Review the activity objectives and CME/CE information.
• Complete the CME/CE activity
• Complete the online posttest. A score of at least 75% is required to successfully complete this activity. The participant may take the test until successfully passed.
• Complete the CME/CE evaluation/attestation form, which provides each participant with the opportunity to comment on how participating in the activity will affect their professional practice; the quality of the instructional process; the perception of enhanced professional effectiveness; the perception of commercial bias; and his/her views on future educational needs.
• Credit documentation/reporting:
• If you are requesting AMA PRA Category 1 Credits™ or a certificate of participation—your CME/CE certificate will be available for download.
• If you are requesting MOC credit, your MOC points will be submitted electronically to the ACCME, which will register data and notify certifying boards.

ACCREDITED PROVIDER
This activity is provided by The France Foundation

TARGET AUDIENCE
This activity is intended for dermatologists, oncologists, and other clinicians involved in the management of patients with locally advanced/metastatic CSCC.

ACCREDITATION STATEMENT
The France Foundation is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CREDIT DESIGNATION
Physicians
The France Foundation designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ABIM MOC Recognition Statement

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Nurses
Nurses who are certified by the American Nurses Credentialing Center (ANCC) may utilize activities that are certified by ACCME-accredited providers toward their requirement for certification renewal by the ANCC. A certificate of attendance will be provided by The France Foundation, an ACCME accredited provider.

DISCLOSURE POLICY
In accordance with the ACCME Standards for Commercial Support, The France Foundation (TFF) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. TFF resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs. Furthermore, TFF seeks to verify that all scientific research referred to, reported, or used in a CME/CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. TFF is committed to providing learners with high-quality CME/CE activities that promote improvements in health care and not those of a commercial interest.

Activity Staff Disclosure
The planners, reviewers, editors, staff, CME committee, or other members at The France Foundation who control content have no relevant financial relationships to disclose.

Faculty Disclosures-Content Creators

The following faculty report that they have relevant financial relationships to disclose:

• Chrysalyne D. Schmults, MD, reports that she has consulted for Regeneron and Sanofi and has served as chair of the National Comprehensive Cancer Network.
• Michael K. Wong, MD, PhD, FRCPC, reports that he has consulted for Bristol Myers Squibb, EMD-Serono, Merck, Pfizer, and Regeneron.

MOC Reviewer Disclosures:

• Theodore Bruno, MD, FACEHP, reports that his spouse is employed by Allergan.
• Vishal Anil Patel, MD, FAAD, FACMS, reports that he has consulted and served on speakers bureaus for Sanofi and Regeneron.

DISCLOSURE OF UNLABELED USE
TFF requires CME faculty (speakers) to disclose when products or procedures being discussed are off label, unlabeled, experimental, and/or investigational, and any limitations on the information that is presented, such as data that are preliminary, or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that is outside of US Food and Drug Administration approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. TFF does not recommend the use of any agent outside of the labeled indications. If you have questions, contact the Medical Affairs Department of the manufacturer for the most recent prescribing information.

COMMERCIAL SUPPORT ACKNOWLEDGMENT
This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc and Sanofi Genzyme.

DISCLAIMER

The France Foundation presents this information for educational purposes only. The content is provided solely by faculty who have been selected because of recognized expertise in their field. Participants have the professional responsibility to ensure that products are prescribed and used appropriately on the basis of their own clinical judgment and accepted standards of care. The France Foundation and the commercial supporter(s) assume no liability for the information herein.

COPYRIGHT INFORMATION
Copyright © 2019 The France Foundation. Any unauthorized use of any materials on the site may violate copyright, trademark, and other laws. You may view, copy, and download information or software ("Materials") found on the Site subject to the following terms, conditions, and exceptions:

• The materials are to be used solely for personal, noncommercial, informational and educational purposes. The materials are not to be modified. They are to be distributed in the format provided with the source clearly identified. The copyright information or other proprietary notices may not be removed, changed, or altered.

• Materials may not be published, uploaded, posted, transmitted (other than as set forth herein), without The France Foundation's prior written permission.

PRIVACY POLICY
The France Foundation protects the privacy of personal and other information regarding participants and educational collaborators. The France Foundation will not release personally identifiable information to a third party without the individual's consent, except such information as is required for reporting purposes to the ACCME.

The France Foundation maintains physical, electronic, and procedural safeguards that comply with federal regulations to protect against the loss, misuse, or alteration of information that we have collected from you.

Additional information regarding The France Foundation’s Privacy Policy can be viewed at https://www.francefoundation.com/privacy.

CONTACT INFORMATION
If you have questions about this CME activity, please contact The France Foundation at 860-434-1650 or info@francefoundation.com.